The novel bronchodilator navafenterol: A Phase 2a, multicentre, randomised, double-blind, placebo-controlled crossover trial in COPD

This Phase IIa randomized, double-blind, crossover study evaluated the efficacy, pharmacokinetics, and safety of navafenterol, as compared with placebo or umeclidinium/vilanterolan, in 73 patients with moderate-to-severe COPD. The study assessed reduction in cough as an exploratory endpoint, which was objectively measured using the Vitalograph VitaloJAK cough monitor.